Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Public ClinicalTrials.gov record NCT04198766. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
Study identification
- NCT ID
- NCT04198766
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 340 participants
Conditions and interventions
Conditions
Interventions
- INBRX-106 - Hexavalent OX40 agonist antibody Drug
- pembrolizumab 200 mg Drug
- pembrolizumab 400 mg Drug
- Carboplatin AUC-5 Drug
- Carboplatin AUC-6 Drug
- Pemetrexed 500 mg/m2 Drug
- Cisplatin 75mg/m2 Drug
- Paclitaxel 200mg/m2 Drug
- Nab paclitaxel 100mg/m2 Drug
- Gemcitabine (1000 mg/m2) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 9, 2019
- Primary completion
- Jun 30, 2033
- Completion
- Jun 30, 2033
- Last update posted
- Jul 28, 2026
2019 – 2033
United States locations
- U.S. sites
- 30
- U.S. states
- 17
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | Recruiting |
| Los Angeles Cancer Network | Glendale | California | 91204 | Recruiting |
| California Research Institute | Los Angeles | California | 90027 | Recruiting |
| Valkyrie Clinical Trials | Los Angeles | California | 90069 | Recruiting |
| Valkyrie Clinical Trials | Murrieta | California | 92562 | Recruiting |
| Providence Medical Foundation | Santa Rosa | California | 95403 | Recruiting |
| Clermont Oncology Center | Clermont | Florida | 34711 | Recruiting |
| Mid Florida Hematology and Oncology Center | Orange City | Florida | 32763 | Recruiting |
| Winship Cancer Institute - Emory University | Atlanta | Georgia | 30322 | Recruiting |
| The University of Chicago Medical Center | Chicago | Illinois | 60637 | Active, not recruiting |
| University of Iowa | Iowa City | Iowa | 52242 | Active, not recruiting |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | Recruiting |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | Completed |
| Henry Ford Cancer Institute | Detroit | Michigan | 48202 | Recruiting |
| START Midwest | Grand Rapids | Michigan | 49546 | Active, not recruiting |
| HealthPartners Cancer Research Center | Saint Louis Park | Minnesota | 55426 | Active, not recruiting |
| HealthPartners Cancer Research Center (Regions Hospital) | Saint Paul | Minnesota | 55101 | Completed |
| Intermountain Health Cancer Centers of Montana | Billings | Montana | 59102 | Completed |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | Recruiting |
| Montefiore Medical Center | The Bronx | New York | 10467 | Active, not recruiting |
| Cleveland Clinic | Cleveland | Ohio | 44195 | Active, not recruiting |
| Providence Portland Medical Center | Portland | Oregon | 97213 | Active, not recruiting |
| Vanderbilt University School of Medicine | Nashville | Tennessee | 37204 | Active, not recruiting |
| Sarah Cannon Research Institute at Mary Crowley | Dallas | Texas | 75230 | Completed |
| Renovatio Clinical - El Paso | El Paso | Texas | 79915 | Completed |
| NEXT Oncology | San Antonio | Texas | 78229 | Completed |
| Renovatio Clinical | The Woodlands | Texas | 77380 | Completed |
| The University of Texas Health Science Center at Tyler | Tyler | Texas | 75701 | Recruiting |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | Completed |
| Froedtert Hospital and the Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | Active, not recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04198766, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 28, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04198766 live on ClinicalTrials.gov.